CDD-0102
| CDD-0102 | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
CDD-0102 is an investigational drug currently under development for the treatment of neurological disorders. It is being studied for its potential effects on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Mechanism of Action[edit]
CDD-0102 is believed to function as a neuroprotective agent, potentially modulating pathways involved in neuronal survival and synaptic plasticity. The exact mechanism of action is still under investigation, but preclinical studies suggest that CDD-0102 may influence neurotransmitter systems and reduce oxidative stress in the brain.
Pharmacokinetics[edit]
The pharmacokinetic profile of CDD-0102 is characterized by its absorption, distribution, metabolism, and excretion (ADME) properties. Preliminary studies indicate that CDD-0102 has a moderate bioavailability and is primarily metabolized in the liver. The elimination half-life of CDD-0102 is approximately 12 hours, allowing for potential once-daily dosing.
Clinical Trials[edit]
CDD-0102 is currently in Phase II clinical trials. Early results have shown promise in improving cognitive function in patients with mild to moderate Alzheimer's disease. Further studies are ongoing to evaluate its efficacy and safety in larger populations and across different stages of neurodegenerative diseases.
Potential Side Effects[edit]
As with any investigational drug, CDD-0102 may have side effects. Commonly reported adverse effects in clinical trials include nausea, headache, and dizziness. Long-term safety data are still being collected.
Research and Development[edit]
CDD-0102 was developed by a collaboration between academic institutions and pharmaceutical companies. The research is funded by grants from various health organizations and aims to address the unmet needs in treating neurodegenerative disorders.
Also see[edit]
Ad. Transform your life with W8MD's Budget GLP-1 injections from $75
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $75 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
